ASH 2020 | Long-term momelotinib exposure in JAKi-naïve or previously JAKi-treated myelofibrosis patients

Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses the long-term outcome data from the Phase III SIMPLIFY trials (S1, NCT01969838; S2, NCT02101268) of momelotinib therapy in intermediate- or high-risk myelofibrosis (MF) patients. Momelotinib is a JAK1/2 and ACVR1 inhibitor, demonstrated to be effective against anemia, splenomegaly, and constitutional symptoms in JAK inhibitor (JAKi)-naïve and previously JAKi-treated MF patients participating in the SIMPLIFY-1 and SIMPLiFY-2 trials, respectively. Long term outcome data from S1 and S2, which compared momelotinib to ruxolitinib or best available therapy, showed similar survival outcomes across the treatment arms in both trials. Transfusion independence, an achievement of substantial clinical benefit in MF, was reached in greater proportion in the momelotinib arms compared to the control arms. This analysis showed the reported benefits of momelotinib to be robust and durable. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.